MARKET COMPOSITE
Biotechnology Stocks28-30-2024 20:30:00 PM
Price
$157.98
+ 0.64%
The list of companies include A-Agilent Technologies Inc., ABIO-ARCA biopharma Inc, ABUS-Arbutus Biopharma Corp, ACAD-Acadia Pharmaceuticals Inc, ACET-Adicet Bio Inc, ACHV-Achieve Life Sciences Inc., ACOR-Acorda Therapeutics Inc, ADMA-Adma Biologics Inc, ADTX-Aditx Therapeutics Inc, ADVM-Adverum Biotechnologies Inc, AEZS-Aeterna Zentaris Inc., AFMD-Affimed N.V., AGEN-Agenus Inc, AGIO-Agios Pharmaceuticals Inc, AGLE-Aeglea BioTherapeutics Inc, AIM-AIM ImmunoTech Inc, AKBA-Akebia Therapeutics Inc., ALDX-Aldeyra Therapeutics Inc, ALEC-Alector Inc, ALIM-Alimera Sciences Inc., ALKS-Alkermes plc, ALLO-Allogene Therapeutics Inc, ALNY-Alnylam Pharmaceuticals Inc, ALPN-Alpine Immune Sciences Inc, ALVR-AlloVir Inc, AMGN-AMGEN Inc., AMTI-Applied Molecular Transport Inc, ANAB-AnaptysBio Inc, ANIX-Anixa Biosciences Inc, APLT-Applied Therapeutics Inc
* Latest intraday update before market close @ 19:45:42 PM 03/28/2024
Summary
:
Average return is up 0.6%
Median return is down 0.0%
108 out of 225 stocks are up (limited to those with intraday pricing feeds).
Top Movers
:
NTLA + 2.1%MORF + 2.2%NERV + 2.2%RLAY + 2.3%RYTM + 2.4%PSTX + 2.4%CUE + 2.4%CLGN + 2.5%XBIT + 2.5%NNVC + 2.7%PDSB + 2.9%INAB + 2.9%ITOS + 2.9%PRLD + 2.9%EDAP + 3.0%RNA + 3.0%LRMR + 3.1%BDTX + 3.2%SNDX + 3.2%PSNL + 3.4%XOMA + 3.5%IGMS + 4.1%ALPN + 4.2%DCPH + 4.3%ANAB + 4.3%PULM + 4.3%DMAC + 4.3%EXAS + 4.4%RCUS + 4.7%CMRX + 5.0%ESPR + 5.0%LCTX + 5.0%ZNTL + 5.0%ENTA + 5.1%IOVA + 5.1%ATHA + 5.5%ALDX + 5.5%DYAI + 5.5%FHTX + 6.1%VNDA + 6.4%MBOT + 7.0%SPRB + 7.3%ASNS + 7.7%APRE + 8.9%MREO + 9.2%CRBP + 9.6%LXRX + 9.6%CLRB + 9.6%APTO + 10.0%SMMT + 10.5%NXTC + 10.9%OPK + 12.2%PTN + 14.4%SRRK + 14.4%IPHA + 15.3%CASI + 19.7%MESO + 42.4%

Aggregated price index with volume information

Summary:

  • Biotechnology stocks up 0.6% on average while median return up 0.0% in a day
  • Biotechnology stocks up 1.8% on average while median return up -0.0% in a week
  • Biotechnology stocks up 1.4% on average while median return up -4.0% in a month
  • When average return is significantly different from median return, this implies an asymmetry - composite return is driven by some outliners.

Aggregated price index (close) is based on equal weighted constituencies returns. Average short volume and average total volumes are averaged across all volume data among constituencies.

Related Stocks
Ticker
1d
7d
30d
PE Ratio
PE/G
P/B (mrq)
P/S (ttm)
Earning Growth
MarketCap
Short %
Held By Institutions %
RSI
Price Pattern
Resist Support
Days Since Channel Change
Channel Slope (daily rate %)
MESO43.6%
116.9%
142.0%
-0.291.83178.61510.2M2%86\99-1.1%
OTLK27.4%
69.6%
2629.1%
-11.9421.183.1B1%9%84-/Above resistance5349.3%
IPHA21.5%
19.5%
9.1%
4.04229.6M0%63
CASI20.3%
18.4%
-36.6%
2.1412.2448M5%39%40-/\57-0.7%
PTN16.9%
15.4%
-23.7%
-0.732.15-371.2030.2M3%11%45\/Below support990.2%
APVO15.5%
4.7%
2912.2%
7.2728.25109.6M5%67%61-\Above resistance54-60.4%
NXTC15.2%
32.7%
39.4%
0.150.7861.4M4%54%75-/\/Above resistance600.9%
SRRK15.0%
3.3%
5.8%
4.4370.741.4B13%100%59\-/1590.8%
EQ12.1%
-16.6%
-11.2%
-5.891.8679.7M7%30%49\-/At support765.1%
OPK12.1%
29.0%
21.8%
-4.783.211.461.44836.4M14%30%74/-\-218-0.1%
APTO10.7%
5.7%
-10.3%
2.5425.9M4%55%50\120-0.4%
SMMT10.4%
16.6%
-8.6%
-2.848.51882.952.9B2%10%51/\/1780.5%
CRBP10.3%
2.9%
40.1%
-105.042.7288.14409.6M10%47%57/-/Below support5912.8%
APRE10.2%
5.4%
-7.1%
35.9M28%57%53\/520.6%
MREO10.0%
11.5%
-11.5%
223.6M85%50/-\-/2181.2%
LXRX9.6%
-0.4%
-8.0%
-2.98-0.34.3941.81588.5M5%85%51/\433-0.1%
CLRB9.5%
2.8%
1.0%
1.7648.8M3%39%56\/800.6%
CDTX9.3%
14.6%
27.7%
-2.75-0.0452.058.2184.3M3%48%73\/-\Above resistance155-0.3%
INM8.0%
-2.7%
-14.6%
-0.252.2M12%49-\-52-0.0%
SGMO7.3%
-30.9%
-37.4%
-0.450.523.4612.42119.3M12%56%43/\218-0.4%
* P/E and MarketCap are refreshed daily using IEX Cloud service. P/B, P/S, PEG, growth, short%, HelbyInstitute are refreshed weekly using Yahoo feeds. For latest stock stats please visit Yahoo Finance.
* Price Patter: / is upward trend, \ is downward trend, - is sideway. Click on the ticker to go to stock page to see Bayesian Trend model plot of the time series.
* Channel and change points are derived from Bayesian Trend model, where the channel slope is the growth rate while change points are those the model partition the time series.
Detail Performance Summary
  • 1M winners are : Winners for past month are $ADVM 617.8%, $XTLB 226.9%, $MESO 142.0%, $RNA 67.2%, $STOK 65.2%
  • 1M losers are : Losers for past month are $EDIT -33.0%, $LRMR -34.0%, $CASI -36.6%, $NDRA -48.2%, $SPRB -85.4%
  • 1W winners are : Winners for past week are $STOK 125.4%, $MESO 116.9%, $LIXT 46.4%, $NXTC 32.7%, $OPK 29.0%
  • 1W losers are : Losers for past week are $ANIX -15.4%, $SYRS -15.6%, $NKTX -16.7%, $PDSB -18.9%, $NDRA -38.3%
Pick two stocks to compare:

Correlation Analysis

Index correlation analysis

Correlation for the past month is 10.5%, for the past 3 months is 11.5%

In the past month for a 5 days rolling window, the highest corrrelation is 22.9%, the lowest correlation is 3.3%, the latest correlation is 13.0%

When a correlation deviated from the normal level and goes lower or even negative, it indicates some of stocks have deviated from the normal direction of the group. The deviation could reverse if long term level of correlation was at a higher level. It creates trading opportunities and deserves study whether the deviation is idiosyncratic or systematic.

Among pairwise correlation, the highest correlation is 63.7% between A and ALLO

The lowest correlation is -44.7% between ACAD and ARMP

Stock news

    NEW YORK, March 28, 2024 (GLOBE NEWSWIRE) -- Applied Therapeutics, Inc. (Nasdaq: APLT), a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates against validated molecular targets in indications of high unmet medical need, today announced that the U.S. Food and Drug Administration (FDA) has extended the review period for the New Drug Application (NDA) for govorestat (AT-007) for the treatment of Classic Galactosemia by three months. The FDA has set a new Prescri

    Crispr stock is down for the fifth straight week as the top Cathie Wood's holding struggles amid dim expectations for its gene-editing drug.

    ANN ARBOR, Mich., March 28, 2024--ENDRA Life Sciences Inc. (NASDAQ: NDRA), a pioneer of Thermo Acoustic Enhanced UltraSound (TAEUS®), today reports financial results for the three months and year ended December 31, 2023 and provides a business update.

    Precigen, Inc. (Nasdaq: PGEN), a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the lives of patients, today announced that the Company has teamed up with the Recurrent Respiratory Papillomatosis Foundation (RRPF) to launch the first RRP Awareness Day™ on June 11, 2024, a multi-stakeholder event to raise awareness about recurrent respiratory papillomatosis (RRP) and bring together RRP patients and their caregivers to encourage new conne

    WALTHAM, Mass., March 28, 2024 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet medical needs, today announced that on March 25, 2024, the compensation committee of the company’s board of directors granted a non-qualified stock option award to purchase 205,000 shares of its common stock and a restricted stock unit award for 160,000 shares in

    BOTHELL, Wash., March 28, 2024--Immunome, Inc. (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, today announced financial results for the full year ended December 31, 2023, and provided an overview of recent developments.

    Publication of annual report for financial year 2023Annual Shareholders’ Meeting resolutions include approval of revised Remuneration Policy and (re)appointment of Board membersExtraordinary Shareholders’ Meeting resolutions include approval of renewal of authorized capital and issuance of Gilead Subsequent Warrant B Mechelen, Belgium; 28 March 2024, 21.01 CET; regulated information – Galapagos NV (Euronext & NASDAQ: GLPG) today publishes its annual report for the financial year 2023 and announc

    Company to host conference call at 4:30 PM EDT today, Thursday, March 28, 2024SEATTLE and VANCOUVER, British Columbia, March 28, 2024 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (NASDAQ: ACHV), a late-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation and nicotine dependence, today announced fourth quarter and year-end 2023 financial results and provided an update on the cytisinicline development program. Recent Highl

    Closed a $6.0 million convertible note in a private placement, with a conversion price of $1.79 and no warrantsReported positive topline data from First-In-Human Phase 1 trial demonstrated clinical safety and antibody response for DYAI-100 a recombinant protein receptor binding domain (RBD) booster vaccine candidate for protection against COVID-19 infection Entered into several fully funded vaccine and antibody projects covering more than twelve targets since announcing topline clinical safety d

    Key Insights Seres Therapeutics' Annual General Meeting to take place on 4th of April CEO Eric Shaff's total...